A neutrophil response linked to tumor control in immunotherapy.

Humans Neutrophils Lung Neoplasms / genetics Signal Transduction / genetics Immunotherapy Interferons
IRF1 SiglecF anti-CD40 anti-PD-1 cancer immunotherapy interferon lung cancer neutrophil single-cell RNA-seq

Journal

Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066

Informations de publication

Date de publication:
30 03 2023
Historique:
received: 03 09 2022
revised: 10 01 2023
accepted: 24 02 2023
pmc-release: 30 03 2024
medline: 4 4 2023
entrez: 31 3 2023
pubmed: 1 4 2023
Statut: ppublish

Résumé

Neutrophils accumulate in solid tumors, and their abundance correlates with poor prognosis. Neutrophils are not homogeneous, however, and could play different roles in cancer therapy. Here, we investigate the role of neutrophils in immunotherapy, leading to tumor control. We show that successful therapies acutely expanded tumor neutrophil numbers. This expansion could be attributed to a Sell

Identifiants

DOI: 10.1016/j.cell.2023.02.032 PMID: 37001504 PMC: PMC10132778
pubmed: 37001504
pii: S0092-8674(23)00210-6
doi: 10.1016/j.cell.2023.02.032
pmc: PMC10132778
mid: NIHMS1879702
pii:
doi:

Substances chimiques

Interferons 9008-11-1

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1448-1464.e20

Subventions

Organisme : NCI NIH HHS
ID : R01 CA218579
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA257623
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA240239
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests M.J.P. has served as consultant for AstraZeneca, Elstar Therapeutics, ImmuneOncia, KSQ Therapeutics, Merck, Siamab Therapeutics, Third Rock Ventures, and Tidal. R.W. has served as a consultant for Moderna, Lumicell, Seer Biosciences, Earli, and Accure Health. The wife of R.B. is an employee and shareholder of CSL Behring, and R.B. received a speaker’s fee from Janssen.

Références

J Exp Med. 2000 Nov 20;192(10):1515-20
pubmed: 11085753
Genome Biol. 2018 Feb 6;19(1):15
pubmed: 29409532
Ann Oncol. 2022 Jan;33(1):67-79
pubmed: 34562610
Cell. 2021 Jun 10;184(12):3163-3177.e21
pubmed: 33964209
Science. 2018 Sep 28;361(6409):
pubmed: 30262472
J Natl Cancer Inst. 2014 May 29;106(6):dju124
pubmed: 24875653
Cell. 2021 Aug 19;184(17):4512-4530.e22
pubmed: 34343496
Circ Res. 2020 Oct 9;127(9):e232-e249
pubmed: 32811295
Nat Commun. 2017 Feb 01;8:14381
pubmed: 28146145
J Clin Invest. 2014 Dec;124(12):5466-80
pubmed: 25384214
Nat Commun. 2021 May 17;12(1):2856
pubmed: 34001893
J Immunother Cancer. 2018 Jul 16;6(1):74
pubmed: 30012216
Nature. 2018 Aug;560(7719):494-498
pubmed: 30089906
Cell Rep. 2018 Jun 26;23(13):3946-3959.e6
pubmed: 29949776
J Immunother Cancer. 2020 Sep;8(2):
pubmed: 32912924
Elife. 2021 May 28;10:
pubmed: 34047696
Nat Biotechnol. 2020 Dec;38(12):1408-1414
pubmed: 32747759
Trends Immunol. 2019 Jul;40(7):584-597
pubmed: 31153737
Sci Transl Med. 2021 Aug 11;13(606):
pubmed: 34380768
Immunity. 2019 Sep 17;51(3):451-464.e6
pubmed: 31471108
Immunity. 2020 Aug 18;53(2):319-334.e6
pubmed: 32814027
J Exp Med. 2022 Jun 6;219(6):
pubmed: 35522219
Cell. 2018 Nov 1;175(4):1014-1030.e19
pubmed: 30343900
Bioinformatics. 2018 Apr 1;34(7):1246-1248
pubmed: 29228172
Cell Rep. 2016 Jun 21;15(12):2719-32
pubmed: 27292635
Sci Rep. 2022 Feb 28;12(1):3278
pubmed: 35228603
Nat Methods. 2017 Sep;14(9):865-868
pubmed: 28759029
Oncoimmunology. 2019 Jun 11;8(9):e1624129
pubmed: 31428521
Genome Biol. 2019 Dec 23;20(1):296
pubmed: 31870423
Nucleic Acids Res. 2019 Jul 2;47(W1):W212-W224
pubmed: 31114921
Cell Rep. 2020 Sep 22;32(12):108164
pubmed: 32966785
Cell. 2020 Oct 29;183(3):838
pubmed: 33125896
Cancer Cell. 2016 Jul 11;30(1):120-135
pubmed: 27374224
Nat Protoc. 2017 Jan;12(1):44-73
pubmed: 27929523
Cancer Res. 2018 May 15;78(10):2680-2690
pubmed: 29490946
Immunity. 2022 Feb 8;55(2):308-323.e9
pubmed: 34800368
Nature. 2016 Nov 10;539(7628):309-313
pubmed: 27806376
Nat Protoc. 2009;4(7):1064-72
pubmed: 19561589
Nature. 2019 Feb;566(7745):553-557
pubmed: 30728496
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
Immunity. 1996 Nov;5(5):491-501
pubmed: 8934575
Immunity. 2018 Oct 16;49(4):764-779.e9
pubmed: 30332632
Nat Med. 2021 May;27(5):820-832
pubmed: 33958794
J Exp Med. 2021 Jan 4;218(1):
pubmed: 33601412
Cell. 2020 Oct 29;183(3):771-785.e12
pubmed: 33125892
Cancer Cell. 2014 Nov 10;26(5):638-52
pubmed: 25446897
Cell. 2020 Jun 25;181(7):1643-1660.e17
pubmed: 32470396
Nat Commun. 2021 Aug 9;12(1):4791
pubmed: 34373452
Cancer Cell. 2021 May 10;39(5):649-661.e5
pubmed: 33711272
Sci Immunol. 2021 Jul 9;6(61):
pubmed: 34244313
Sci Immunol. 2021 Jul 2;6(61):
pubmed: 34215680
Nat Cell Biol. 2019 Sep;21(9):1113-1126
pubmed: 31451770
Immunity. 2019 Jun 18;50(6):1498-1512.e5
pubmed: 31097342
Immunity. 2020 Aug 18;53(2):303-318.e5
pubmed: 32579887
JCI Insight. 2019 Dec 19;4(24):
pubmed: 31852845
Nature. 2015 Jun 18;522(7556):345-348
pubmed: 25822788
Sci Immunol. 2021 Oct 29;6(64):eabi8800
pubmed: 34714687
Immunity. 2018 Feb 20;48(2):364-379.e8
pubmed: 29466759
Cell Rep. 2015 Dec 29;13(12):2829-2841
pubmed: 26711347
Cancer Cell. 2015 Dec 14;28(6):785-799
pubmed: 26678340
Cell. 2019 Jul 11;178(2):346-360.e24
pubmed: 31257026
Semin Immunol. 2021 Oct;57:101538
pubmed: 34876331
Cancer Cell. 2009 Sep 8;16(3):183-94
pubmed: 19732719
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Immunity. 2016 Feb 16;44(2):343-54
pubmed: 26872698
Front Immunol. 2018 Dec 04;9:2867
pubmed: 30564248
Cancer Immunol Res. 2016 Oct;4(10):845-857
pubmed: 27589875
FASEB J. 2020 Mar;34(3):4204-4218
pubmed: 31957112
Science. 2017 Dec 1;358(6367):
pubmed: 29191879
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
Nat Commun. 2020 Jun 2;11(1):2762
pubmed: 32488020
Nature. 2019 Aug;572(7770):538-542
pubmed: 31367040
Nat Commun. 2022 Aug 9;13(1):4658
pubmed: 35945238
Cancer Cell. 2011 Sep 13;20(3):300-14
pubmed: 21907922
Br J Cancer. 2013 Mar 5;108(4):914-23
pubmed: 23385730
Nat Rev Clin Oncol. 2019 Oct;16(10):601-620
pubmed: 31160735
Nat Immunol. 2020 Sep;21(9):1119-1133
pubmed: 32719519
Nature. 2020 Jul;583(7814):133-138
pubmed: 32528174
Semin Immunol. 2021 Oct;57:101506
pubmed: 34711490
Immunity. 2012 Dec 14;37(6):1091-103
pubmed: 23123063
Proc Natl Acad Sci U S A. 1998 May 26;95(11):6239-44
pubmed: 9600949
Immunity. 2019 May 21;50(5):1317-1334.e10
pubmed: 30979687
Cell. 2015 May 21;161(5):1187-1201
pubmed: 26000487
Genome Biol. 2008 Oct 30;9(10):235
pubmed: 18983710
Oncoimmunology. 2016 Sep 13;5(11):e1232221
pubmed: 27999744
Immunity. 2018 Dec 18;49(6):1148-1161.e7
pubmed: 30552023

Auteurs

Jeremy Gungabeesoon (J)

Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA.

Nicolas A Gort-Freitas (NA)

Department of Systems Biology, Harvard Medical School, Boston, MA, USA.

Máté Kiss (M)

Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland; AGORA Cancer Research Center, Lausanne, Switzerland.

Evangelia Bolli (E)

Department of Systems Biology, Harvard Medical School, Boston, MA, USA; Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland; AGORA Cancer Research Center, Lausanne, Switzerland.

Marius Messemaker (M)

Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.

Marie Siwicki (M)

Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA.

Mehdi Hicham (M)

Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland; AGORA Cancer Research Center, Lausanne, Switzerland.

Ruben Bill (R)

Department of Systems Biology, Harvard Medical School, Boston, MA, USA; Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland; AGORA Cancer Research Center, Lausanne, Switzerland.

Peter Koch (P)

Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA.

Chiara Cianciaruso (C)

Department of Systems Biology, Harvard Medical School, Boston, MA, USA; Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland; AGORA Cancer Research Center, Lausanne, Switzerland.

Florent Duval (F)

Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland; AGORA Cancer Research Center, Lausanne, Switzerland.

Christina Pfirschke (C)

Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA.

Michael Mazzola (M)

Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA, USA.

Solange Peters (S)

Service of Medical Oncology, Department of Oncology, CHUV, Lausanne, Switzerland; Department of Oncology, University of Lausanne, Lausanne, Switzerland.

Krisztian Homicsko (K)

AGORA Cancer Research Center, Lausanne, Switzerland; Ludwig Institute for Cancer Research, Lausanne, Switzerland; Department of Oncology, CHUV, Lausanne, Switzerland; Swiss Cancer Center Leman, Lausanne, Switzerland.

Christopher Garris (C)

Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA.

Ralph Weissleder (R)

Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA; Department of Systems Biology, Harvard Medical School, Boston, MA, USA.

Allon M Klein (AM)

Department of Systems Biology, Harvard Medical School, Boston, MA, USA. Electronic address: allon_klein@hms.harvard.edu.

Mikael J Pittet (MJ)

Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA; Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland; AGORA Cancer Research Center, Lausanne, Switzerland; Ludwig Institute for Cancer Research, Lausanne, Switzerland; Swiss Cancer Center Leman, Lausanne, Switzerland. Electronic address: mikael.pittet@unige.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › A neutrophil response linked to tumor control...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Phagocytes › Granulocytes neutrophiles › A neutrophil response linked to tumor control...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › A neutrophil response linked to tumor control...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › A neutrophil response linked to tumor control...
questionsmedicales.fr › Thérapeutique › Biothérapie › Immunothérapie › A neutrophil response linked to tumor control...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Interférons › A neutrophil response linked to tumor control...